Background {#Sec1}
==========

Considerable progress has been made in understanding the biology and therapeutic potential of adult stem cells since the first report of human hematopoietic stem cell transplantation in 1957 \[[@CR1]\]. Mesenchymal stem or stromal cells (MSCs) were originally described in the 1960s as a subset of fibroblast-like cells in the bone marrow capable of undergoing osteogenic differentiation \[[@CR2]\]. Minimum criteria defining human MSCs were established by the International Society for Cellular Therapy in 2006 \[[@CR3]\] and include: plastic adherence under standard culture conditions; expression of the surface markers CD73, CD90, and CD105 and lack of expression of hematopoietic markers as well as HLA-DR; and ability to undergo adipogenic, chondrogenic, and osteogenic differentiation in vitro. In 2013, CD29 and CD44 were added to the list of MSC-positive surface markers \[[@CR4]\]. Furthermore, the origin of MSCs in multiple body tissues, including human endometrium \[[@CR5], [@CR6]\], has been traced to perivascular cells expressing CD146, NG2, PDGFRβ, and α-SMA. Expression of these markers is maintained by human MSCs in culture \[[@CR7]\]. Moreover, studies in vitro and using cell transplantation in model species have shown that, in addition to providing different types of precursor cells, MSCs contribute to tissue repair through immunomodulatory, antiapoptotic, antimicrobial, and a variety of other trophic effects that act to enhance endogenous repair mechanisms \[[@CR8]\]. Based on these findings, several hundred clinical trials are currently being carried out using human MSCs \[[@CR9]\].

In the horse, MSCs have been used clinically for about 15 years, with therapeutic benefit reported in the treatment of several orthopedic conditions. Equine MSCs are commonly harvested from bone marrow or adipose tissue and are expanded in vitro before use in autologous transplants \[[@CR10]--[@CR13]\]. The requirement to use surgical procedures to harvest cells from those locations has driven the search for other---less invasive---sources including whole blood, umbilical cord blood, or Wharton jelly \[[@CR14]--[@CR17]\]. In that regard, the endometrium represents an attractive alternative source of MSCs in the horse.

Endometrial cells meeting the criteria of MSCs have already been harvested and characterized from humans, rodents, pigs, dogs, and sheep \[[@CR18]--[@CR25]\]. In addition to undergoing trilineage differentiation, they can reportedly generate muscle and neuronal lineages \[[@CR5], [@CR26]\]. The therapeutic potential of endometrial MSCs has already been demonstrated in relation to premature ovarian failure \[[@CR27]\], Parkinson's disease \[[@CR26]\], and pelvic organ prolapse \[[@CR28]\], although these uses have yet to be proven clinically.

The equine endometrium is highly dynamic, cyclically undergoing remodeling \[[@CR29]\] which suggests the presence of an active population of mesenchymal precursor cells, yet this has not been investigated. With the goal of eventually exploring the therapeutic potential of these cells, this study aimed to isolate and characterize equine endometrial MSCs and compare their properties to those of the well-characterized bone marrow (BM)-derived MSCs.

Methods {#Sec2}
=======

Samples and materials {#Sec3}
---------------------

Equine reproductive tracts were collected post mortem from five prepubertal (18-month-old) Welsh Cob ponies and one 6-year-old warmblood mare during diestrus. Bone marrow samples were collected from three Welsh Cob ponies. The animals were euthanized at the School of Veterinary Studies of the University of Edinburgh or the School of Veterinary Medicine of the University of Glasgow for reasons not related to any reproductive tract pathology. All animal procedures were carried out according to the UK Home Office Animals (Scientific Procedures) Act 1986 with approval by the Ethical Review Committee, University of Edinburgh (60/4207). All chemicals and reagents used for cell culture in the study were obtained from Life Technologies (Thermo Fisher Scientific, Paisley, UK) unless otherwise specified, and culture plastic ware (Nunc™) was purchased from Sigma Aldrich (St Louis, MO, USA).

Immunohistochemistry {#Sec4}
--------------------

Small pieces of equine endometrium (5 mm × 5 mm) were snap frozen and cut into 5-μm sections using a Leica CM1900 cryotome. The tissue sections were fixed in ice-cold methanol:acetone (50:50) for 10 minutes and washed three times with phosphate buffered saline (PBS) before incubation with a Protein Block (Spring Bioscience) for 45 minutes at room temperature. The sections were then incubated overnight at 4 °C with the primary antibodies presented in Table [1](#Tab1){ref-type="table"}. Another three washes with PBS were followed by incubation with the secondary antibody (Table [1](#Tab1){ref-type="table"}) for 30 minutes at room temperature. Finally, the nuclei were counterstained for 3 minutes with 4′,6-diamidine-2′-phenylindole dihydrochloride (DAPI) before mounting. Sections were visualized under a Leica DM LB2 fluorescence microscope.Table 1Antibodies selected for immunohistochemistry and flow cytometry characterization of equine MSCsAntibodyHost, isotypeEpitopeCloneCompanyCD29Mouse, IgG1,κHumanTS2/16BioLegendCD44Mouse, IgG1HorseCVS18AbD SerotecCD90Mouse, IgG1,κRatOX-7BD PharmingenCD105Mouse, IgG1HumanSN6AbD SerotecNG2:APCMouse, IgG1HumanLHM-2R&D SystemsCD146:FITCMouse, IgG1HumanOJ79cAbD SerotecCD34:PEMouse, IgG1Human4H11\[APG\]Immuno ToolsMHC-II:FITCMouse, IgG1HorseCVS20AbD SerotecMucin-1Goat, IgGPolyclonalSanta CruzSecondary antibodies IgG---AF568DonkeyMousePolyclonalInvitrogen IgG---AF488GoatMousePolyclonalInvitrogen IgG---AF568DonkeyGoatPolyclonalInvitrogenIsotype controls Mouse IgG1, κMOPC-21BioLegend Mouse IgG111711R&D Systems Mouse IgG1:APC11711R&D Systems Mouse IgG1:PEPPV-06Immuno Tools Mouse IgG1:FITCAbD Serotec Goat IgGSanta Cruz*MSC* mesenchymal stromal/stem cell

Isolation of equine endometrial stromal cells {#Sec5}
---------------------------------------------

One gram of endometrial tissue was stripped from the underlying myometrium and dissociated using mechanical and enzymatic digestion as described previously \[[@CR20]\] with a few modifications. In short, the tissue pieces were washed twice in PBS and minced before dissociation in DMEM/F-12 containing 0.1% bovine serum albumin (BSA), 0.5% collagenase I, 40 μg/ml deoxyribonuclease type I (Sigma Aldrich), and 1% penicillin/streptomycin for 40 minutes at 37 °C in a SI50 Orbital Incubator (Stuart Scientific). The resulting cell solution was filtered through a sterile 70-μm cell strainer (Fisher Scientific) to separate single cells from undigested tissue fragments. After washing with MSC culture medium consisting of DMEM/F-12 containing 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin, and centrifugation for 5 minutes at 720 × *g*, the resulting cell pellet was resuspended in Ca^2+^ and Mg^2+^-free PBS supplemented with 0.1% FBS and 2 mM sodium citrate.

Magnetic Dynabeads M-450 that had been coated with a Mucin-1 antibody (Santa Cruz) according to the manufacturer's protocol were utilized to remove epithelial cells from the single cell suspension. The number of Mucin-1-coated beads required was calculated assuming 50% of the cell suspension was epithelial. Four beads were incubated per epithelial cell for 40 minutes at 4 °C with gentle rotation and tilting. Unbound (stromal, Muc-1^--^) and bound (epithelial, Muc-1^+^) cell fractions were collected using a Dynamagnet 2, centrifuged, and cultured in MSC culture medium at an initial density of 10^6^ cells/75 cm^2^ in a humidified incubator at 37 °C in 5%CO~2~:95% air. Medium was changed every 2--3 days.

Isolation of equine bone marrow-derived MSCs {#Sec6}
--------------------------------------------

Bone marrow was scraped out of the sternum and immersed in 30 ml PBS containing 45 mg ethylenediaminetetraacetic acid (EDTA) in a 50-ml Falcon tube. The tube was gently rotated and tilted to wash out cells from the bone marrow matrix. The solution was filtered through a 40-μm cell strainer (Fisher Scientific) and centrifuged at 720 × *g* for 5 minutes. The resulting cell pellet was resuspended in PBS. To remove red blood cells, 4 ml of the BM cell solution was underlaid with 3 ml Ficoll Paque PLUS (GE Healthcare) and centrifuged at 20 °C for 40 minutes at 400 × *g*. The interphase layer of mononuclear cells was collected, washed twice with PBS, and cultured at an initial density of 20--40 million cells/175 cm^2^ in MSC culture medium under the same conditions already described for the endometrial-derived stromal cells.

Colony forming unit assay {#Sec7}
-------------------------

Doubling times (DTs) of endometrial Muc-1^--^ fraction cells (*n* = 6 horses) and BM MSCs (*n* = 3 horses) in culture were calculated between passages 1 and 2 using the following equation:$$\documentclass[12pt]{minimal}
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where *T* is the incubation time in days, and *X* ~b~ and *X* ~e~ are the cell numbers at the beginning and the end, respectively, of the incubation time.

Endometrial Muc-1^--^ fraction cells and BM MSCs, both at passage 2, were seeded in triplicate at clonal densities of 5 and 10 cells/cm^2^ in six-well plates and cultured in MSC medium in a humidified atmosphere at 37 °C in 5% CO~2~:95% air. Medium was changed every 3--4 days, and on the 12th day of culture cells were washed with PBS and fixed with 10% buffered formalin for 1 hour. Cultures were then stained with crystal violet (Sigma Aldrich) for 10 minutes, washed three times with dH~2~O, and dried at room temperature.

Cell clusters that were visible without magnification and contained more than 50 cells were defined as colonies. Cloning efficiency (CE) was calculated with the following formula:$$\documentclass[12pt]{minimal}
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Flow cytometry {#Sec8}
--------------

Endometrial Muc-1^--^ cells (*n* = 6 horses) and BM MSCs (*n* = 3 horses) at passage 3 or 4 were analyzed using flow cytometry. The cultured cells were lifted with TrypLE, washed with complete MSC culture medium, and centrifuged at 720 × *g* for 5 minutes at room temperature. Cell pellets were resuspended in PBS containing 5% FBS and incubated for 45 minutes on ice. Cells were then incubated with directly conjugated or unconjugated primary antibodies to different cell surface markers or with matched isotype control IgG (Table [1](#Tab1){ref-type="table"}) for 1 hour at 4 °C. After three washes with PBS, cells were incubated with AF488-conjugated secondary antibodies for 30 minutes at 4 °C. Cells were analyzed using a LSR Fortessa™ flow cytometer (BD Biosciences) equipped with FACS Diva software and the collected data (10000 events) were analyzed with FlowJo (V10; LLC).

Cross-reactivity of cell surface marker antibodies was tested by IHC and flow cytometry, and the expression of each marker was confirmed via RT quantitative polymerase chain reaction (qPCR).

qPCR analyses {#Sec9}
-------------

RNA was extracted using TRIzol reagent from freshly collected endometrial cells (*n* = 6 horses) and from cultures of endometrial Muc-1^--^ cells (*n* = 6 horses) and BM MSCs (*n* = 3 horses) at passages 1 and 4. RNA was analyzed using a spectrophotometer (ND-1000, Nano Drop®) and total RNA (0.5--1 μg) was reverse-transcribed using SuperScript III following the instructions of the manufacturer. Subsequent qPCR reactions were performed using SensiFAST™ SYBR® Lo-ROX Kit (Bioline) and equine primers (Table [2](#Tab2){ref-type="table"}) in a Stratagene Mx3000P qPCR machine (Agilent technologies). Data were analyzed with MxPRO qPCR software (Agilent technologies). Values were calculated relative to a standard curve prepared from a pool of samples run simultaneously. Three reference genes were analyzed for stability using the web-based comprehensive tool RefFinder \[[@CR30]\] integrating geNorm, BestKeeper, Normfinder, and the comparative ΔCt method. Data were normalized using RNA levels of 18S.Table 2Primers used for qPCR analysisMarkerPrimer sequence (5′--3′)Reference gene*18S*ForwardGCT GGC ACC AGA CTT GReverseGGG GAA TCA GGG TTC G*TBP*ForwardCCA AGC GTT TTG CTG TAReverseTTC ACT CTT GGC TCC CG*GAPDH*ForwardGAA GAT GTG GCG CGA TGG CCReverseACT GAC ACG TTA GGG GTG GGG ACMSC markerCD29ForwardGGC TAA CAG GGA GTT TCA GATReverseACA TCT ATT TTC ATC TGC TTG GCCD44ForwardCCC ACG GAT CTG AAA CAA GTGReverseTTC TGG AAT TTG AGG TCT CCG TATCD90ForwardTGC GAA CTC CGC CTC TCTReverseGCT TAT GCC CTC GCA CTT GCD105ForwardGAC GGA AAA TGT GGT CAG TAA TGAReverseGCG AGA GGC TCT CCG TGT TPerivascular markerCD146ForwardCTG GAC TTG GAA ACC ACA ACA TCReverseCAG GTC TCA CTC GGA CAT CAG ANG2ForwardCGA ATC ATT GGG CCC TAC TTReverseGCT GTT CCA CCT CTC TCC AGHematopoietic markerCD34ForwardCAC TAA ACC CTC TAC ATC ATT TTC TCC TAReverseGGC AGA TAC CTT GAG TCA ATT TCACD45ForwardTGA TTC CCA GAA ATG ACC ATG TAReverseACA TTT TGG GCT TGT CCT GTA ACEpithelial markerMucin-1ForwardCTA TCT CGT TGC CCT GGC TGReverseGTA GGC ATC ACG GGT TGG AASmooth muscle markerACTA2ForwardCTA ACA ACG TCC TCT CCG GGReverseCTG CTG GAA GGT GGA CAG AGCNN1ForwardCGG CAA CTT CAT GGA CGReverseTTC TCC AGC TGG TGC CAA TMHY11ForwardATC CAT CCT GAC CCC ACG TAReverseCGG AAG AGC CGC TCA TAA GT*MSC* mesenchymal stromal/stem cell, *qPCR* quantitative polymerase chain reaction

In-vitro trilineage differentiation {#Sec10}
-----------------------------------

Endometrial Muc-1^--^ cells and BM MSCs (from three horses each) were used separately at passage 3 or 4. For adipogenic differentiation, cells were seeded in triplicate wells of 12-well plates (5000/cm^2^) with MSC culture medium for 2--4 days before changing medium to DMEM/F-12 containing 7% rabbit serum, 3% FBS, 1% penicillin/streptomycin, 1 μM dexamethasone (Sigma Aldrich), 0.5 mM 3-isobutyl-1-methylxanthine (IBMX) (Sigma Aldrich), 10 μg/ml insulin (Sigma Aldrich), and 100 μM indomethacin (Sigma Aldrich). After 5 days of culture, cells were washed with PBS before fixation in 10% formalin and were stained with Oil Red O (Sigma Aldrich) for 10 minutes.

For osteogenic differentiation, cells were seeded in triplicate wells of 12-well plates (5000 cells/cm^2^) and cultured for 2--4 days before changing medium to DMEM/F-12 containing 10% FBS, 1% penicillin/streptomycin, 10 mM β-glycerophosphate (Sigma Aldrich), 100 nM dexamethasone (Sigma Aldrich), and 200 μM [l]{.smallcaps}-ascorbic acid 2-phosphate (Sigma Aldrich). Medium was changed every 2--3 days and after 3 weeks cells were washed with PBS, fixed in 10% formalin, and stained with Alizarin Red (Sigma Aldrich) for 45 minutes.

For chondrogenic differentiation, 3 × 10^5^--4 × 10^5^ cells were centrifuged in a V-bottomed 96-well plate at 720 × *g* for 5 minutes. After centrifugation, without disturbing the freshly formed pellet, medium was changed to DMEM/F-12 containing 1% penicillin/streptomycin, 1% ITS+ premix (Corning), 100 nM dexamethasone (Sigma Aldrich), 200 μM [l]{.smallcaps}-ascorbic acid 2-phosphate (Sigma Aldrich), 100 μg/ml sodium pyruvate (Sigma Aldrich), and 10 ng/ml TGF-β1 (R&D Systems). After 24 hours of incubation, the pellets were gently loosened and transferred to a U-bottom 96-well plate with a cell-repellent surface (Greiner bio-one). Micro masses were cultured for 28 days with medium changes every 1--2 days and then fixed in 10% formalin for 24 hours. The pellets were processed and embedded in paraffin. Sections were cut on a microtome (Leica RM2235) and stained with Alcian Blue (Acros Organics) and the nuclear counter stain Nuclear Fast Red (Sigma Aldrich).

In-vitro smooth muscle differentiation {#Sec11}
--------------------------------------

The protocol used for smooth muscle differentiation was adapted from Guo et al. \[[@CR31]\]. In short, endometrial Muc-1^--^ cells and BM MSCs (from three horses each) at passage 3 or 4 were seeded at a density of 70,000 cells/well in triplicate wells of 12-well plates and incubated at 37 °C in 5%CO~2~:95% air for 24 hours before the medium was changed to DMEM containing 1% FBS. After a further 24 hours, differentiation was induced by changing the medium to DMEM containing 1% FBS and 1 ng/ml TGF-β1 (R&D Systems). Control cells were maintained in MSC culture medium and after 7 days all cells were harvested using TRIzol reagent and processed for qPCR analysis as described earlier.

Statistical analysis {#Sec12}
--------------------

All data were analyzed using IBM SPSS Statistics 22 software using each donor horse as the experimental unit. Normal distribution was tested with the Shapiro--Wilk test and data were log-transformed if necessary. Flow cytometry data were analyzed using Levene's test for equality of variances and a two-tailed *t* test. QPCR data were analyzed with two-way ANOVA and Tukey's test. Data are shown as mean ± SEM. Significance was set at *p* \< 0.05.

Results {#Sec13}
=======

Localization of MSC and perivascular markers in equine endometrium {#Sec14}
------------------------------------------------------------------

Endometrial tissue was analyzed for the presence of a selection of cluster of differentiation (CD) antigens commonly used to identify human MSCs, namely CD29, CD44, CD90, and CD105 (Fig. [1a](#Fig1){ref-type="fig"}), as well as the perivascular cell surface markers, CD146 and NG2 (Fig. [1b](#Fig1){ref-type="fig"}). CD29 and CD44 were localized mainly around blood vessels. Milder staining for CD29 was found around endometrial glands and underneath the epithelium. CD90 clone 5E10 was very abundant throughout the stroma, except in glandular cells (data not shown), indicating lack of specificity. CD90 clone OX7 staining was present throughout the endometrial stroma in a string-like pattern, and also around endometrial glands. CD105 staining was less abundant and localized within single cells throughout the stroma. All MSC markers tested were absent from glandular cells and the endometrial epithelium. The perivascular markers, CD146 and NG2, were mostly located around the blood vessel walls.Fig. 1Immunohistochemistry of equine endometrial sections. Photomicrographs show localization of (**a**) MSC markers CD29, CD44, CD90, and CD105 and (**b**) perivascular markers NG2 and CD146 within the equine endometrium. DAPI was used to stain cell nuclei. *Yellow arrows*, endometrial glands; *white arrows*, blood vessels. *DAPI* 4′,6-diamidine-2′-phenylindole dihydrochloride (Color figure online)

Isolation and culture of endometrial MSCs {#Sec15}
-----------------------------------------

Culture of endometrial tissue directly following collagenase dissociation resulted in epithelial cells adhering quickly to plastic culture ware and eventually outgrowing the stromal cells (Fig. [2a](#Fig2){ref-type="fig"}). Thus, we used magnetic beads bound to Muc-1, a surface marker located within the luminal and glandular epithelium (Fig. [2b](#Fig2){ref-type="fig"}), to enrich endometrial digests for stromal cells. The resulting Muc-1^--^ fraction, from here onward referred to as endometrial MSCs, was used for culture (Fig. [2c](#Fig2){ref-type="fig"}).Fig. 2Isolation and culture of MSCs. **a** Micrograph showing cells cultured directly following digestion of equine endometrium. Using this procedure, clusters of epithelial cells (*black arrows*) eventually outgrew stromal cells in culture. **b** Section of equine endometrium stained for Mucin-1, showing positive cells in epithelia and glands (*white arrows*). Cell nuclei stained with DAPI. **c** Micrograph of endometrial stromal cells in culture obtained after separation of epithelial cells (shown in **d**) using beads bound to Mucin-1. **e** Cell colonies produced after seeding of endometrial and BM MSCs at low densities. **f** Cloning efficiencies (*CE*) for endometrial MSCs (*n* = 6 horses) and BM MSCs (*n* = 3 horses) at two different seeding densities. *Scale bars*: 1 mm (**a**, **c**--**e**). *BM* bone marrow, *MSC* mesenchymal stromal/stem cell (Color figure online)

Upon initial seeding, endometrial MSCs attached quickly and evenly over the entire culture surface in contrast to BM MSCs which took longer to adhere and tended to grow in clusters. Moreover, doubling times between passages 1 and 2 tended to be shorter for endometrial MSCs than for BM MSCs (2.8 ± 0.6 vs 5.2 ± 1.9 days, respectively, *p* = 0.09). Cloning efficiency (CE) assays performed at passage 2 yielded similar results for both endometrial and BM MSCs, as shown in Fig. [2e, f](#Fig2){ref-type="fig"}.

Expression of MSC and perivascular markers by endometrial MSCs in culture {#Sec16}
-------------------------------------------------------------------------

The expression of MSC and perivascular cell surface markers was analyzed by qPCR and flow cytometry in endometrial and BM MSCs at different passages (Figs. [3](#Fig3){ref-type="fig"} and [4](#Fig4){ref-type="fig"}). Moderate differences were detected in transcript levels of MSC markers, including higher overall levels of CD29 and, to a lesser degree, CD105, in endometrial MSCs than in BM MSCs (as indicated in each case by a significant effect of cell type), as well as a slight reduction in overall CD29 levels between passages 1 and 4 (Fig. [3](#Fig3){ref-type="fig"}). Flow cytometry (Fig. [4](#Fig4){ref-type="fig"}) showed all of these markers to be present, on average, in ≥97% of endometrial and BM MSCs (except for CD105, detected in 80% of BM MSCs). Moreover, there was an overall increase in transcript levels of CD146 between passages 1 and 4 (Fig. [3](#Fig3){ref-type="fig"}). The levels of another perivascular marker, NG2, did not change with passage but were lower in endometrial MSCs than in BM MSCs (Fig. [3](#Fig3){ref-type="fig"}), a result that was confirmed by flow cytometry data (Fig. [4](#Fig4){ref-type="fig"}). Finally, CD34 and MHC-II were expressed by a minority of cells (≤2%) in both endometrial and BM MSC cultures (Fig. [4](#Fig4){ref-type="fig"}), whereas CD45 was detectable in BM MSCs at passage 1 only (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Transcript levels (arbitrary units) of cell surface markers in cultured MSCs. Expression of MSC markers (CD29, CD44, CD90, CD105), perivascular markers (NG2, CD146), and hematopoietic markers (CD34, CD45) quantified by qPCR in endometrial MSCs (*n* = 6 horses, *white bars*) and BM MSCs (*n* = 3 horses, *gray bars*) in culture at passages 1 and 4. All results shown as mean ± SEM. Significant main effects (*p* \< 0.05) of passage, cell type, and passage × cell type interaction obtained by two-way ANOVA are shown. *AU* arbitrary units Fig. 4Flow cytometry analysis. Representative flow cytometry histograms with percentages of endometrial and BM MSCs (*n* = 6 and *n* = 3 horses, respectively) positive for different MSC, perivascular, and hematopoietic cell surface markers. *Grey areas*, signal from isotype controls; *black lines*, signal from the specific cell surface marker. *BM* bone marrow, *MSC* mesenchymal stromal/stem cell

In-vitro differentiation of endometrial MSCs {#Sec17}
--------------------------------------------

The ability of endometrial MSCs to undergo trilineage differentiation was assessed in parallel with that of BM MSCs. Endometrial MSCs differentiated into adipogenic, osteogenic, and, albeit to a lesser degree than BM MSCs, chondrogenic lineages (Fig. [5](#Fig5){ref-type="fig"}).Fig. 5Trilineage differentiation of endometrial MSCs (**a**, **c**, **e**) and BM MSCs (**b**, **d**, **g**). Representative images of endometrial and BM MSCs (*n* = 3 horses each) after differentiation and staining with Oil red O (**a**, **b**), Alizarin Red (**c**, **d**) and Alcian Blue/Nuclear Fast Red (**e**--**g**) to assess differentiation into adipogenic, osteogenic, and chondrogenic lineages, respectively. *Insets* show nondifferentiated control cells (**a**--**d**). Nondifferentiated control BM MSCs used in chondrogenic differentiation experiments shown in (**f**). *Scale bars*: 100 μm (**a**, **b**), 500 μm (**c**, **d**, **e**, **g**) and 1 mm (**f**)

Additionally, the relative capacity of the two types of MSCs to differentiate into smooth muscle, a key component of the myometrium in the uterus, was determined by treating cells with TGF-β1. Endometrial MSCs, but not BM MSCs, underwent morphological changes primarily characterized by shortening of the cell body in response to treatment (Fig. [6a, b](#Fig6){ref-type="fig"}). Because of the difficulty of clearly distinguishing smooth muscle cells from undifferentiated MSCs, we assessed the expression of early (ACTA2), intermediate (CNN1), and mature (MYH11) smooth muscle markers \[[@CR31]\] in endometrial and BM MSC cultures by qPCR (Fig. [6c](#Fig6){ref-type="fig"}). Results showed an increase in mean transcript levels of the intermediate marker, CNN1, in BM MSCs (1.7-fold, *p* \< 0.05) and, particularly, in endometrial MSCs (2.9-fold, *p* \< 0.0001) between days 0 and 7, and an increase in the levels of the mature smooth muscle marker, MYH11, only in endometrial MSCs (1.8-fold, *p* \< 0.005).Fig. 6Smooth muscle differentiation. Micrographs showing (**a**) endometrial MSCs (*n* = 3 horses) and (**b**) BM MSCs (*n* = 3 horses) induced to differentiate into smooth muscle for 7 days. *Insets* show noninduced control cells. *Scale bars*: 500 μm. **c** Expression of smooth muscle markers in endometrial MSCs (*white bars*) and BM MSCs (*grey b*ars) before (*d0*) and on day 7 (*d7*) of differentiation. Results shown as mean ± SEM. Significant main effects (*p* \< 0.05) of day, cell type, and day × cell type interaction obtained by two-way ANOVA are shown. *AU* arbitrary units

Discussion {#Sec18}
==========

MSCs---defined by their adherence to plastic, expression of a subset of cell surface markers, and ability to differentiate into adipogenic, osteogenic, and chondrogenic lineages \[[@CR3]\]---have to this date been isolated from several body tissues including bone marrow, fat, umbilical cord, placenta, amniotic fluid, umbilical cord blood, peripheral blood, and endometrium \[[@CR32]--[@CR35]\]. Bone marrow and adipose tissue have been the most common sources of clinical MSCs in horses, and they are also the most common sources used for clinical trials in humans. Collection of MSCs from these locations requires relatively invasive procedures involving sedation and local anesthesia, and carries the potential of postsurgical complications \[[@CR36]\]. Thus, alternative sources of equine MSCs, such as the endometrium, are desirable. A major advantage of isolating MSCs from the endometrium compared to bone marrow or adipose tissue is that cells can be harvested by biopsy collection \[[@CR24], [@CR37]\], which is a relatively noninvasive approach used routinely in horses for diagnostic purposes that does not require sedation or local anesthesia \[[@CR38]\]. In this study, we show for the first time that putative MSCs contained within the equine endometrium can be harvested and expanded in vitro, and have characteristics that may prove useful for tissue regeneration applications.

Endometrial MSCs had typical spindle-shaped morphology, indistinguishable from that of BM MSCs; however, they tended to grow faster than BM MSCs following initial seeding, as indicated by their mean doubling time values. In contrast, cloning efficiencies (CE) at passage 2 were similar for the two cell types, around 25--30%, and comparable to previous reports from 27% \[[@CR39]\] to 34% \[[@CR40]\] for equine BM MSCs. The faster initial growth of endometrial MSCs relative to BM MSCs may be conferred by their native in-vivo environment characterized by fast tissue turnover during the estrous cycle. If confirmed in future studies, this property of endometrial MSCs may provide an advantage over other MSC sources because it may allow shortening of the interval between collection of tissue samples and transplant of in-vitro expanded MSCs, which is a serious limitation of current BM and adipose MSC treatments in horses. In addition, based on cell yields obtained from 1 g of endometrial tissue (≥10^7^ Muc-1^--^ cells) and considering subsequent growth rates in culture (see Results), we estimate that a typical 0.2--0.4 g biopsy would readily yield \>10 million cells after short-term expansion, a sufficient number for therapy applications in horses. Furthermore, when executed appropriately, the biopsy procedure does not result in damage or scarring of the uterus. Indeed, it has been shown that repeated collection of multiple biopsies (up to five each time) before estrus had no effect on subsequent pregnancy rates in mares \[[@CR41]\].

Cells staining for CD44, CD105, CD146, and NG2 were located primarily around blood vessels within the equine endometrium, consistent with the identification of perivascular cells as native counterparts of MSCs in many different human tissues \[[@CR7], [@CR42]\], including the endometrium \[[@CR6]\]. By contrast, CD90 (clone OX7) followed a less restricted pattern throughout the stroma to include nonperivascular cells. The distinct abundance of CD90 compared to the other MSC markers tested suggests that this may not be an appropriate marker for equine MSCs in the endometrium.

Consistent with the definition of MSCs, endometrial stromal cells robustly maintained the expression of CD29, CD44, CD90, and CD105 in culture, as well as, to a lesser extent, perivascular markers, whilst having negligible expression of hematopoietic markers and MHC-II, in agreement with previous studies with human endometrial-derived MSCs \[[@CR5], [@CR25], [@CR27], [@CR43]\]. A limited number of studies have compared the features of endometrial MSCs with MSCs from other sources \[[@CR23], [@CR44]\]. Our finding based on results of flow cytometry and qPCR, showing that endometrial MSCs in culture display moderately higher levels of CD29, CD90, and CD105 but lower levels of NG2 than their BM counterparts, is consistent with data from Indumathi et al. \[[@CR23]\]. Whether this is indicative of differences in the abundance of stem cells between the two tissue sources or reflects tissue-specific changes in immunophenotype that may be induced in culture should be investigated in future studies.

That endometrial and BM MSCs have different properties was confirmed by the results of differentiation assays; specifically by the observation that while endometrial MSCs were able to undergo trilineage differentiation, their ability to generate cartilage was lower than that of BM MSCs based on a clearly reduced intensity of Alcian Blue staining in endometrial MSC-derived chondrogenic pellets (Fig. [5](#Fig5){ref-type="fig"}). In contrast, the opposite was observed in relation to the ability of MSCs to adopt a smooth muscle phenotype, as evidenced by a distinct increase in endometrial MSCs, but not in BM MSCs, in the levels of the mature smooth muscle marker, MYH11, after treatment with TGF-β1. There is evidence that significant differentiation bias can be conferred by the tissue of origin of MSCs \[[@CR45]\]. For example, while human multipotent cell populations from the myometrium and skeletal muscle had a similar immunophenotype and ability to differentiate into smooth muscle, only skeletal muscle-derived progenitors were able to undergo osteogenic and adipogenic differentiation \[[@CR46]\]. In light of this, a distinct ability of endometrial MSCs (compared to BM MSCs) to differentiate into smooth muscle may be related to the presence of a large smooth muscle component in the uterus, the myometrium. Whether our observation alternatively reflects the presence, natural or through contamination during sample collection, of myometrial precursor cells, different from MSCs, in the endometrial stroma needs to be investigated in future studies. Nonetheless, a reported intrinsic ability of human endometrial MSCs to differentiate into smooth muscle provides the rationale for specific therapeutic applications already being sought for these cells (e.g., pelvic organ prolapse) \[[@CR47]\].

Conclusion {#Sec19}
==========

We report for the first time the identification, culture, and characterization of stromal cells within the equine uterus that fulfill the definition of MSCs based on clonogenicity, immunophenotype, and ability to differentiate into different mesenchymal derivatives. Although not addressed in this study, the relative abundance and phenotype of MSCs in the equine endometrium may vary with the reproductive stage, a possibility that should be investigated in the future. Endometrial MSCs may provide an easily accessible alternative to therapeutic applications that currently use bone marrow and adipose MSCs in the horse. They may moreover provide a new therapeutic venue for equine uterine disease, a multifaceted and highly prevalent condition which significantly impairs fertility in mares. With this in mind, future studies should be aimed at exploring the clinical regenerative potential of these cells in the endometrium but also in other tissues that have been more commonly targeted with cell therapies, such as musculoskeletal tissue.
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